Amylyx Pharmaceuticals Shares Surge Nearly 79% on Positive Trial Results and Analyst Upgrades
Amylyx Pharmaceuticals (NASDAQ: AMLX) saw its stock rise nearly 79% over five trading days following positive Phase 3 clinical trial results for avexitide, a GLP-1 medication targeting post-bariatric hypoglycemia. The drug met both primary and secondary endpoints, showing significant improvement in reducing severe hypoglycemic events compared to placebo. The stock's surge was further fueled by analyst upgrades, including Guggenheim’s Seamus Fernandez raising his price target from $40 to $55 per share while maintaining a 'buy' rating. Amylyx also announced an upsized secondary offering of up to $500 million, which it plans to use primarily for avexitide-related efforts. Despite concerns about potential dilution, the company's market cap now exceeds $4.3 billion, and analysts remain optimistic due to the drug’s strong performance in trials and lack of FDA-approved alternatives currently available.
Tickers: $AMLX